Morpholino

MO2-dre-mir-19b

ID
ZDB-MRPHLNO-161222-9
Name
MO2-dre-mir-19b
Previous Names
  • MO2-mir19b
Target
Sequence
5' - GCTGAATGCAAACCAGCAAAACTGA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO2-dre-mir-19b
Phenotype
Phenotype resulting from MO2-dre-mir-19b
Phenotype of all Fish created by or utilizing MO2-dre-mir-19b
Phenotype Fish Conditions Figures
whole organism kcnj2a expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
heart contraction decreased frequency, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 3 with imageFig. 6 with image from Benz et al., 2016
whole organism kcne4 expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
cardiac ventricle ventricular cardiac muscle cell action potential increased duration, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 4 with image from Benz et al., 2016
whole organism kcnj2b expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
whole organism scn1ba expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
whole organism scn4ba expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
whole organism kcne1 expression increased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 5 with image from Benz et al., 2016
whole organism dre-mir-19b expression decreased amount, abnormal WT + MO2-dre-mir-19b standard conditions Fig. 3 with image from Benz et al., 2016
cardiac ventricle cardiac muscle contraction decreased frequency, abnormal twu34Tg + MO2-dre-mir-19b chemical treatment by environment: Terfenadine Fig. 4 with image from Benz et al., 2016
cardiac muscle cell action potential involved in contraction duration, ameliorated kcnh6am230/+ + MO2-dre-mir-19b standard conditions Fig. 6 with image from Benz et al., 2016
cardiac muscle cell action potential involved in contraction decreased duration, abnormal kcnh6am230/m230 + MO2-dre-mir-19b standard conditions Fig. 6 with image from Benz et al., 2016
heart contraction frequency, ameliorated WT + MO1-kcne4 + MO2-dre-mir-19b standard conditions Fig. 6 with image from Benz et al., 2016
Citations